Press Detail





Biotest AG: Sale of Microbiological Monitoring business to Merck KGaA completed

Biotest AG / Key word(s): Disposal

01.08.2011 / 17:19

---------------------------------------------------------------------

Sale of Microbiological Monitoring business to Merck KGaA completed

- Transaction has been successfully closed today after clearance of merger
  control authorities was given
- Biotest focusses now on Plasmaproteins and Biotherapeutics


Dreieich, 1st August, 2011. All relevant merger control authorities
approved the sale of Biotest's AG woldwide activities of its
Microbiological Monitoring business, consisting of the productportfolio of
HYCON (hygiene monitoring), the productportfolio of heipha Dr. Müller GmbH
(microbiological culture media and microbiological test systems) to Merck
KGaA, Darmstadt. Biotest AG and Merck KGaA therefore closed the deal today,
which had been agreed upon on 21st March 2011 and which was subject to
merger approval.

According to the terms of the transaction, Merck will acquire two
production sites in Germany, as well as four subsidiaries - the heipha Dr.
Müller GmbH (51% Biotest; 49% Dr. Müller) the Biotest Microbiology Corp.
(Rockaway, New Jersey, USA), the Biotest S.à.r.l (Paris, France) and the
Biotest K.K. (Yokohama, Japan). The transaction also comprises the 49%
shares of Dr. Müller of heipha Dr. Müller GmbH. In addition Merck acquires
the microbiological monitoring businesses of five of Biotest Group's
european subsidiaries under an asset deal.
 
With the disposal, the Biotest Group intends to sharpen its focus on
developing and marketing innovative pharmaceutical and biotherapeutic
drugs in immunology and haematology.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein segment, Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. In the
Biotherapeutic segment, Biotest researches into the clinical development of
monoclonal antibodies, including in the indications of rheumatoid arthritis
and cancer of plasma cells. Biotest has more than 1.600 employees
worldwide. The preference shares of Biotest AG are listed in the SDAX on
the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406, 
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart


End of Corporate News

---------------------------------------------------------------------

01.08.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     Biotest AG                                             
             Landsteinerstraße 5                                    
             63303 Dreieich                                         
             Germany                                                
Phone:       0 61 03 - 8 01-0                                       
Fax:         0 61 03 - 8 01-150                                     
E-mail:      investor_relations@biotest.de                          
Internet:    http://www.biotest.de                                  
ISIN:        DE0005227235, DE0005227201                             
WKN:         522723, 522720                                         
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
133934 01.08.2011